Company / Free Cash Flow
Neurocrine Biosciences Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$748.7M
FY2025
5-year range
$217.6M / $748.7M
FY2021-FY2025
Trend
+34.4%
vs FY2024
Sector context
#19 of 194
Health Care
What the data says
Among 194 Health Care companies, Neurocrine Biosciences is in the top 10% for free cash flow. Free Cash Flow has increased for 3 consecutive years, from $218M in FY2022 to $749M in FY2025.
Based on SEC 10-K filings.
$749M in FY2025 with a 5-year CAGR of +28.0%. Top quartile in the Health Care sector.
Improved from $362M to $749M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +51.0%
- 5-Year CAGR
- +28.0%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 194This company $748.7M Sector average $470.8M
▼
+59.0% above sector average
Key checks
Key Insights
- Neurocrine Biosciences's free cash flow has grown for 3 consecutive years.
- 5-year CAGR of +28.0%, indicating consistent growth.
- In FY2025, free cash flow increased 34.4% year-over-year.
- Ranks #19 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $748.7M | +34.4% |
| FY2024 | $557.2M | +54.1% |
| FY2023 | $361.6M | +66.2% |
| FY2022 | $217.6M | -6.6% |
| FY2021 | $233.1M | +7.1% |
| FY2020 | $217.6M | +64.5% |
| FY2019 | $132.3M | +72.7% |
| FY2018 | $76.6M | +175.6% |
| FY2017 | -$101.3M | +8.2% |
| FY2016 | -$110.3M | -176.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026